Hepatitis B virus infection in patients with metabolic syndrome: A complicated relationship. Results of a population based study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F14%3A00061004" target="_blank" >RIV/00159816:_____/14:00061004 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15260/14:33151517

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.ejim.2014.01.006" target="_blank" >http://dx.doi.org/10.1016/j.ejim.2014.01.006</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejim.2014.01.006" target="_blank" >10.1016/j.ejim.2014.01.006</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hepatitis B virus infection in patients with metabolic syndrome: A complicated relationship. Results of a population based study

Popis výsledku v původním jazyce

Background: The presence of hepatitis B infection (HBI) and metabolic syndrome (MS) at the same time constitutes a high risk for liver cirrhosis and potentially hepatocellular carcinoma. Aim: In this study we aim to explore the relationship between MS and HBI. Methods: We used data from the cross-sectional HepaMeta study conducted in 2011 in Slovakia. Patients were tested for presence of MS, while lipid levels (total cholesterol, HDL, LDL, TG, apolipoprotein B100 and HBI (HBsAg and antiHBcIgG)) were also monitored. Viral load was measured in HBsAg positive patients. Results: Altogether 855 patients were screened, MS was diagnosed in 25.1% of patients and 7.9% of patients presented with HBI. AntiHBcIgG antibodies were present in 34.6% patients. HBI patients had lower levels of total and LDL cholesterol along with a decreased apolipoprotein B100 (4.54 +/- 0.84 vs. 5.0 +/- 0.99 mmol/l, P = 0.001; 2.29 +/- 0.58 vs. 2.6 +/- 0.68 mmol/l, P = 0.001 and 0.71 +/- 0.21 vs. 0.77 +/- 0.23 mmol/l,

Název v anglickém jazyce

Hepatitis B virus infection in patients with metabolic syndrome: A complicated relationship. Results of a population based study

Popis výsledku anglicky

Background: The presence of hepatitis B infection (HBI) and metabolic syndrome (MS) at the same time constitutes a high risk for liver cirrhosis and potentially hepatocellular carcinoma. Aim: In this study we aim to explore the relationship between MS and HBI. Methods: We used data from the cross-sectional HepaMeta study conducted in 2011 in Slovakia. Patients were tested for presence of MS, while lipid levels (total cholesterol, HDL, LDL, TG, apolipoprotein B100 and HBI (HBsAg and antiHBcIgG)) were also monitored. Viral load was measured in HBsAg positive patients. Results: Altogether 855 patients were screened, MS was diagnosed in 25.1% of patients and 7.9% of patients presented with HBI. AntiHBcIgG antibodies were present in 34.6% patients. HBI patients had lower levels of total and LDL cholesterol along with a decreased apolipoprotein B100 (4.54 +/- 0.84 vs. 5.0 +/- 0.99 mmol/l, P = 0.001; 2.29 +/- 0.58 vs. 2.6 +/- 0.68 mmol/l, P = 0.001 and 0.71 +/- 0.21 vs. 0.77 +/- 0.23 mmol/l,

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Internal Medicine

ISSN

0953-6205

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

286-291

Kód UT WoS článku

000333109300022

EID výsledku v databázi Scopus

—